IP Library › Granted Patent US 8,859,274
Granted Patent B2
US 8,859,274 · App. 11/591,478 · Granted Oct 14, 2014

Antibody fragment-targeted immunoliposomes for systemic gene delivery

Inventors: Liang Xu (Arlington, VA); Cheng-Cheng Huang (Arlington, VA); William Alexander (Rockville, MD); WenHua Tang (Arlington, VA); Esther H. Chang (Chevy Chase, MD)
Assignees: SynerGene Therapeutics, Inc.; Georgetown University
C12N15/86A61K48/0008C12N2810/859A61K47/48561A61K9/0019C12N2710/10343C12N2810/85A61K9/1271A61K47/48823A61K9/1272
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,859,274
App. No.
11/591,478
Granted
Oct 14, 2014
Kind
B2
Abstract

A targeted vector allowing enhanced gene transfer to human hepato-cellular carcinoma (HCC 1 ) cells in vitro was developed using cationic liposomes covalently conjugated with the mAb AF-20. This high affinity antibody recognizes a rapidly internalized 180 kDa cell surface glycoprotein which is abundantly expressed on the surface of human HCC and other cancer cells. Quantitative binding analysis of liposomes with target cells by flow cytometry showed specific association of mAb-targeted liposomes with human HCC cells. Using mAb-targeted cationic liposomes containing 20% DOTAP, in the presence or absence of serum, gene expression in HuH-7 cells was enhanced up to 40-fold as compared to liposomes conjugated with an isotype-matched non-relevant control antibody. Transfection specificity was not observed in a control cell line that does not express the antigen recognized by mAb AF-20. This study demonstrates that cationic liposome formulations can be targeted with monoclonal antibodies (mAbs) to enhance specific in vitro gene delivery and expression in the presence or absence of serum.

Claims (12)

1. A plasmid construct for enhanced gene expression in mammalian cells, comprising, from 5′ to 3′:

(a) human adenovirus 5 (Ad5) enhancer sequences present in map units 0-1 of Ad5, comprising two copies of Element I and a single copy of Element II;

(b) a cytomegalovirus (CMV) promoter;

(c) a multiple cloning site;

(d) a nucleic acid; and

(e) an SV40 poly A sequence;

wherein the 3′ end of the plasmid construct does not comprise adenovirus map units 9-16 when compared to wild-type adenovirus.

2. The plasmid construct of claim 1 , wherein said mammalian cells are human cells.

3. The plasmid construct of claim 1 , further comprising a gene conferring antibiotic resistance to said mammalian cells.

4. The plasmid construct of claim 1 , wherein said nucleic acid encodes wild type p53.

5. A liposome complex comprising (i) a liposome, (ii) a cell-targeting ligand, and (iii) the plasmid construct of claim 1 .

6. A method of expressing a gene in a mammalian cell, comprising contacting the liposome complex of claim 5 with a mammalian cell under conditions suitable for transfection and gene expression.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: ALEXANDER, WILLIAM
To: SYNERGENE THERAPEUTICS, INC.
Reel/Frame 033670/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: XU, LIANG; HUANG, CHENG-CHENG; TANG, WENHUA; CHANG, ESTHER H.
To: GEORGETOWN UNIVERSITY
Reel/Frame 033670/0342 →
Continuity (3)
Continuation 09914046
Provisional Application 60121133 · Feb 22, 1999
Related Publication 20070065432A1 · Mar 22, 2007